Registry Following Advanced Ovarian and Endometrial Cancer Patients in Germany
Collects treatment, disease course and patient-reported information in adults with advanced ovarian or endometrial cancer.
Key facts
- Who runs it
- iOMEDICO AG
- Where
- Multiple Locations, GermanySee the site
- Trial code
- Registry title
- Registry Platform Ovarian and Endometrial Cancer
- Status
- Recruiting
- People taking part
- 1,975 people, planned
- Started
- 25 Nov 2021
- Expected to end
- Dec 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- Physician's choice according to patient's needs.
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with advanced or metastatic ovarian, fallopian tube, primary peritoneal or endometrial cancer who are starting systemic treatment. It is a registry that follows patients over time.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- High grade ovarian, fallopian tube or primary peritoneal cancer, FIGO stage IIb-IV, or recurrent/relapsed disease. Or endometrial cancer that is locally advanced and cannot be operated on, or has spread (FIGO stage III-IV).
- Earlier treatment
- Ovarian cancer: starting systemic treatment, or starting systemic treatment for relapsed disease after earlier systemic anti-tumor treatment. Endometrial cancer: starting systemic first-line therapy.
Main reasons for not taking part
- Newly diagnosed early-stage ovarian cancer (FIGO stage I-IIa)
- Low grade ovarian cancer
- Early-stage endometrial cancer (FIGO stage I-II)
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):; patients with FIGO stage IIb-IV OC who are starting systemic treatment or; patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease
- Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy
- Signed and dated informed consent (IC):; Patients participating in PRO module: IC before first therapy cycle; Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle
Who cannot take part
- newly diagnosed early-stage OC (FIGO stage I-IIa)
- Low grade mOC OR
- Early-stage EC (FIGO stage I-II)
Where in Germany
- Multiple sites all over germanyMultiple Locations, GermanyContact: iOMEDICO AGTaking people
About the trial
What the trial wants to find out
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.
The 2 groups in the trial
- Ovarian cancer
Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer): * with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant/curative or palliative) or * with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent/relapsed disease.
Treatment: Physician's choice according to patient's needs.
- Endometrial cancer
Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
Treatment: Physician's choice according to patient's needs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes
- Plain-language title
- Registry Following Advanced Ovarian and Endometrial Cancer Patients in GermanyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 January 2026